English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Monitoring CMV-specific Cell-mediated immunity (CMV-CMI) has been shown to be useful predicting late-onset CMV infection in different solid organ transplants, but few data has been reported after Lung Transplantation (LT). CMV-CMI against two major CMV antigens (IE-1, pp65) was evaluated in 60 seropositive LT at 6-month prophylaxis withdrawal. LT with late-onset CMV infection showed significantly lower (IE-1)CMV-CMI than patients who did not (p=0.045), being more evident in patients developing high viral loads (p=0.010). Notably, (IE-1)CMV-CMI independently predicted high first late-onset viral replication (OR 4.358, 1.043-18.215).CMV-specific CMI may be a useful new immune tool guiding CMV preventive strategies after LT.

CMV-specific Cell-Mediated Immunity Predicts High level of CMV Replication after Prophylaxis withdrawal in Lung Transplant Recipients